Trial Update November 10, 2026

Relugolix Phase 3 Trial in Prostate Cancer Patients Not Yet Recruiting

A Phase 3 clinical trial involving relugolix was registered as of November 10, 2026. The trial is titled "Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy." According to its listing, the study's current status is not yet recruiting. The trial is registered under identifier NCT07927777. It is designated as a Phase 3 study, focusing on patients with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy surgery. No enrollment has begun according to the available record. No results, outcomes, or efficacy data have been posted at this stage. The trial record does not specify further details such as estimated enrollment numbers or projected start date beyond its current pre-recruitment status. This update reflects only the registration and status information publicly available as of the date listed. Readers interested in the broader pharmacological context, including related compounds such as degarelix, can consult the compound overview for additional background information on this therapeutic class.

See the full degarelix overview

Source: https://clinicaltrials.gov/study/NCT07927777